ixekizumab Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
humanized origin 5083 1143503-69-8

Description:

MoleculeDescription

Synonyms:

  • ixekizumab (genetical recombination)
  • ixekizumab
  • LY2439821
  • taltz
A humanized anti-interleukin 17 monoclonal antibody used for the treatment of PSORIASIS.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
2.90 mg P

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
July 4, 2016 PMDA Eli Lilly Japan
Feb. 25, 2016 EMA
March 22, 2016 FDA ELI LILLY AND CO

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Injection site erythema 471.16 30.21 230 7072 74197 46604563
Injection site reaction 437.56 30.21 191 7111 47658 46631102
Injection site pain 413.64 30.21 238 7064 106914 46571846
Injection site swelling 384.93 30.21 166 7136 40161 46638599
Psoriasis 378.21 30.21 202 7100 78402 46600358
Therapy cessation 298.55 30.21 123 7179 26506 46652254
Therapy interrupted 196.51 30.21 71 7231 10720 46668040
Injection site pruritus 151.89 30.21 88 7214 39655 46639105
Injection site warmth 148.71 30.21 62 7240 13710 46665050
Injection site urticaria 139.80 30.21 57 7245 11910 46666850
Injection site rash 109.02 30.21 52 7250 15761 46662999
COVID-19 106.90 30.21 54 7248 18521 46660239
Ear infection 87.96 30.21 51 7251 22962 46655798
Drug ineffective 77.27 30.21 256 7046 677582 46001178
Sinusitis 73.87 30.21 96 7206 129672 46549088
Psoriatic arthropathy 73.37 30.21 54 7248 36325 46642435
Nasopharyngitis 66.84 30.21 100 7202 153898 46524862
Urticaria 60.59 30.21 83 7219 117809 46560951
Product dose omission issue 60.07 30.21 100 7202 168420 46510340
Tooth infection 54.42 30.21 30 7272 12256 46666504
Pharyngitis streptococcal 49.81 30.21 25 7277 8443 46670317
Injection site mass 48.78 30.21 30 7272 15010 46663750
Injection site bruising 48.49 30.21 42 7260 35594 46643166
Inappropriate schedule of product administration 41.52 30.21 51 7251 64962 46613798
SARS-CoV-2 test positive 40.07 30.21 14 7288 1911 46676849
Influenza 37.27 30.21 57 7245 89213 46589547
Pruritus 36.16 30.21 101 7201 242251 46436509
Surgery 35.31 30.21 32 7270 28753 46650007
Fungal infection 34.62 30.21 32 7270 29488 46649272
Rash 33.65 30.21 127 7175 356385 46322375
Infection 33.29 30.21 68 7234 133524 46545236

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 391.86 29.61 170 4479 42336 29905493
Injection site pain 345.16 29.61 141 4508 30169 29917660
Injection site reaction 287.45 29.61 94 4555 10666 29937163
Injection site erythema 283.43 29.61 99 4550 13735 29934094
Therapy cessation 215.92 29.61 83 4566 15054 29932775
Injection site swelling 188.02 29.61 65 4584 8715 29939114
Drug ineffective 101.60 29.61 185 4464 340202 29607627
Therapy interrupted 94.83 29.61 33 4616 4496 29943333
Injection site rash 90.65 29.61 30 4619 3509 29944320
Nasopharyngitis 90.40 29.61 74 4575 58775 29889054
Injection site pruritus 88.04 29.61 33 4616 5559 29942270
COVID-19 69.66 29.61 40 4609 17838 29929991
Ear infection 69.22 29.61 30 4619 7344 29940485
Sinusitis 59.85 29.61 46 4603 33299 29914530
Pruritus 55.09 29.61 79 4570 118125 29829704
Injection site warmth 53.13 29.61 17 4632 1785 29946044
Infection 51.60 29.61 62 4587 78012 29869817
Product dose omission issue 48.27 29.61 65 4584 91566 29856263
Influenza 47.36 29.61 45 4604 43353 29904476
Injection site bruising 44.33 29.61 22 4627 7316 29940513
Rash 43.11 29.61 93 4556 191796 29756033
Insurance issue 42.44 29.61 12 4637 826 29947003
Injection site mass 39.56 29.61 18 4631 4935 29942894
Wrong technique in device usage process 36.58 29.61 11 4638 940 29946889
Inappropriate schedule of product administration 35.57 29.61 37 4612 39691 29908138
Arthralgia 34.16 29.61 69 4580 135722 29812107
Knee operation 32.66 29.61 11 4638 1355 29946474
Fungal infection 31.72 29.61 22 4627 13578 29934251
Psoriatic arthropathy 31.03 29.61 23 4626 15738 29932091
Cutaneous lymphoma 30.95 29.61 6 4643 76 29947753

Pharmacologic Action:

SourceCodeDescription
ATC L04AC13 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Interleukin inhibitors
MeSH PA D003879 Dermatologic Agents
FDA MoA N0000191494 Interleukin-17A Antagonists
FDA EPC N0000191495 Interleukin-17A Antagonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Ankylosing spondylitis indication 9631008 DOID:7147
Plaque psoriasis indication 200965009

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-17A Cytokine ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D10071 KEGG_DRUG
4035606 VANDF
C3489764 UMLSCUI
CHEMBL1743034 ChEMBL_ID
DB11569 DRUGBANK_ID
C549079 MESH_SUPPLEMENTAL_RECORD_UI
7541 IUPHAR_LIGAND_ID
9467 INN_ID
BTY153760O UNII
1745099 RXNORM
31578 MMSL
d08425 MMSL
016752 NDDF
724037000 SNOMEDCT_US
763603002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
TALTZ HUMAN PRESCRIPTION DRUG LABEL 1 0002-1445 INJECTION, SOLUTION 80 mg SUBCUTANEOUS BLA 30 sections
TALTZ HUMAN PRESCRIPTION DRUG LABEL 1 0002-7724 INJECTION, SOLUTION 80 mg SUBCUTANEOUS BLA 30 sections